Unurjargal, Tsolmon
Loading...
Товч нэр
Unurjargal, Tsolmon
Бүтэн нэр
Unurjargal Tsolmon
Латин нэр
Unurjargal Tsolmon
Албан тушаал
Судлаач
ORCID
Scopus Author ID
4 results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hypertension prevalence and control in Ulaanbaatar, Mongolia(2020-01)Scopus© Citations 18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genealogical Identification and Short Tandem Repeat-Based Verification of Suspected Consanguinity in Mongolian Families(Informa UK Limited, 2026); ; ; PURPOSE: The prevalence of consanguineous marriages remains high in several regions worldwide, particularly the Middle East and South Asia, with a reported rate of 58%. However, the prevalence and genetic characteristics of consanguineous marriages in Mongolia are not well studied. This study aimed to estimate the frequency of consanguineous marriages in selected Mongolian populations, using genealogical and short tandem repeat (STR) analyses. PATIENTS AND METHODS: This cross-sectional study was conducted at the Institute of Biomedicine at the Mongolian National University of Medical Sciences. A total of 574 individuals from 185 families across 43 soums in three provinces (X1, X2, and X3) were included. Genealogical analysis was used to construct pedigree-based consanguinity profiles, and STR analysis was performed to validate biological relatedness in selected families. RESULTS: Seventeen families were consanguineous, with a mean inbreeding coefficient of 0.089 ± 0.136, whereas 42 families were classified as suspected consanguinity. Among the confirmed cases, seven families with complete biological samples were further analyzed using STR markers, of which five showed molecular evidence of consanguinity (probabilities, 76.18-98.84%). The STR analysis of 29 families classified as suspected or non-consanguineous identified 13 families as non-consanguineous and 10 families showing possible or indeterminate relatedness. Notably, six families initially classified as suspected or non-consanguineous demonstrated molecular evidence of consanguinity (probabilities, 70.75-99.85%). Genetic diversity analysis revealed reduced heterozygosity in offspring from consanguineous families (expected heterozygosity [HE] = 0.7580, observed heterozygosity[HO] = 0.7045) compared with offspring from non-consanguineous families (HE = 0.7858, HO = 0.8110), with a significant reduction in HO (p = 0.0009). CONCLUSION: This study demonstrates the value of integrating genealogical and STR-based molecular approaches for the assessment of consanguinity in Mongolia. Molecular analyses identified consanguineous relationships that were not evident from pedigree information alone and revealed reduced genetic diversity among offspring from consanguineous families. These findings provide important baseline data for understanding the genetic consequences of consanguinity in the Mongolian population and support the need for large scale epidemiological and genetic investigation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia(Public Library of Science (PLoS), 2023); ; ; The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21-28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21-28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Diabetes management cascade in Ulaanbaatar, Mongolia(2025)